Physical risk: low to moderate | |
● Blood draw: possible pain associated with needle stick, ecchymosis, or phlebitis | |
● Randomization: subject assignment to the therapeutic group may be less beneficial and associated with more adverse events than standard of care | |
● Other possible risks: osteomyelitis, cellulitis, dermatitis, eczema, rash, allergic reaction | |
● Potential severe but rare risks: cessation of heartbeat and respiratory failure | |
Psychological risk: low | |
● However, no direct causal relationship has been established to therapy with Timoptic-XR®. These rare AEs may include depression, confusion, anxiety, disorientation, nightmares, somnolence, insomnia, diminished concentration, hallucinations | |
Social risk: low | |
● Subjects are required to visit the clinic weekly, which may take time away from other activities and tiredness while waiting for weekly office visits | |
Economic risk: moderately low ● Cost of travel to and from weekly appointments. Due to frequency of visit, subjects may lose time from work. Note: subjects would be required to travel for weekly visits regardless of whether the subject had been enrolled in the study, since standard of care typically requires weekly visits | |
Physical risk: low | |
● All subjects in the study will have their personal information confidentially secured in locked filling cabinets and with protected passwords in a computer database. Access is strictly limited to authorized individual (principal investigator, research staff, or other regulatory authorities such as representatives of FDA or IRB). |